Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Sacha I. Rothschild,Ilaria Alborelli,Katharina Leonards,Laura P. Leuenberger,Spasenija Savic Prince,Kirsten D. Mertz,Severin Poechtrager,Alfred Zippelius,Heinz Läubli,Jasmin Haegele,Markus Tolnay,Lukas Bubendorf,Luca Quagliata,Philip Jermann

Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.

2018

Sacha I. Rothschild
Ilaria Alborelli
Katharina Leonards
Laura P. Leuenberger
Spasenija Savic Prince
Kirsten D. Mertz
Severin Poechtrager
Alfred Zippelius
Heinz Läubli
Jasmin Haegele
Markus Tolnay
Lukas Bubendorf
Luca Quagliata
Philip Jermann

e14266Background: In non-small cell lung cancer (NSCLC) immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive bi...

Keywords:

Cell
Lung cancer
Pathology
Cancer research
Immune checkpoint
Medicine
targeted ngs
overall survival
immune checkpoint inhibitors
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations